ResQ Pharma, Inc., a Chicago-based pharmaceutical company developing and commercializing innovative drug therapies, today announced that it has received a PDUFA (Prescription Drug User Fee Act) date of June 2, 2025, for its LipidRescue Kit. If...
Bracco Diagnostics Inc., the U.S. subsidiary of Bracco Imaging S.p.A., a leading global company in the diagnostic imaging business, is proud to announce that its most recently FDA-approved magnetic resonance imaging (MRI) agent, VUEWAY®...
SystImmune, Inc (SystImmune), a clinical-stage biotechnology company, announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for BL-M17D1, an antibody-drug conjugate (ADC) with a novel...
Transposon Therapeutics, a biotechnology company developing a platform of novel, orally administered therapies for the treatment of neurodegenerative and aging-related diseases, including Alzheimer's disease, announced that results from its Phase...
Aadi Bioscience, Inc. announced financial results for the third quarter ended September 30, 2024, and provided recent corporate progress. "The third quarter saw strong sales growth for FYARRO, backed by continued account momentum, increased demand...
HanAll Biopharma Co., Ltd. a global biopharmaceutical company committed to discovering and developing innovative medicines for patients, reported financial results for the third quarter of 2024 and provided business updates. HanAll ended the third...
French TechBio startup Cure51 and 10x Genomics, Inc., a leader in single cell and spatial biology, announced that Cure51 will deploy 10x Genomics' Visium HD as part of its pioneering work to understand the unique biology of exceptional cancer...
GoodRx the leading prescription savings platform in the U.S., announced the rollout of its new e-commerce solution, with Opill® as its launch partner. This new seamless direct-to-consumer shopping experience allows consumers to order eligible...
Vensica Medical a pioneering urology therapeutics company, announced the successful closing of an $11 million funding round. The investment will fund the company's upcoming Phase 2 clinical trials across the United States and Europe for its...
GC Biopharma announced that it has signed an agreement with Novelty Nobility, a biotech company specializing in the development of antibody-based therapeutics, for the joint research and development of a novel treatment for geographic atrophy...
BioCryst Pharmaceuticals, Inc. announced new real-world comparative research on the use of oral, once-daily ORLADEYO® (berotralstat) that found high rates of adherence and persistence for ORLADEYO, similar to the rates observed with two other...
On October 18th, the new product launch event hosted by Great Bay Bio (hereinafter referred to as "GBB") was successfully held in Suzhou, where industry players gathered to celebrate the feast of technological innovation. At the event, GBB...
in the Randomized Placebo Controlled Double Blind Phase I-IIa ArthemiR™ Trial of ATX-01 for Myotonic Dystrophy. Type 1 (DM1). DM1 is a devastating rare neuromuscular disorder that causes muscle weakness and other life-limiting complications. There...
Clarity Pharmaceuticals a clinical stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer. Is pleased to announce it will be commencing a pivotal...
high-dose LTI-03 (5 mg BID) in 12 patients with IPF. In the trial, eligible patients (n=24) are randomly assigned (3:1) to receive either inhaled LTI-03 or placebo. The primary objective of the trial is to evaluate the safety and tolerability of...
Eisai Saudi Arabia was established in April 2024 in order to build an in-house sales system. Japan-based Eisai Co. has announced that fully-fledged operations and business activities have begun at Eisai Pharmaceuticals Single Person Limited...
Blue Earth Therapeutics Ltd, an emerging leader in the development of therapeutic radiopharmaceuticals, today announced further positive developments for its novel investigational radioligand therapies. Enrolment of patients in the Phase 1 trial...
Prendio-BioProcure, a leader in procurement solutions for the life science industry, is excited to launch PrendioPay, an integrated payment platform that evolves the operational reality that most biotech companies face in their business today –...
with the potential to prolong the IgG-low window. In 2023, Hansa conducted the first-in-human trial of HNSA-5487 (NICE-01) reporting positive high-level results on safety and tolerability and observing complete depletion of IgG antibodies at...
Bruker Corporation announced the acquisition of Dynamic Biosensors GmbH, a pioneering company known for its breakthroughs in biosensor development, which is based in Munich, Germany. This acquisition strengthens Bruker’s biophysical portfolio for...
